Brief: Bristol Myers Squibb Diversifies Oncology Portfolio With Acquisition Of Mirati Therapeutics

Mirati Therapeutics

08/10/2023 22:42

Oct 9 (Reuters) - Bristol-Myers Squibb Co  BMY.N :
    * BRISTOL MYERS SQUIBB STRENGTHENS AND DIVERSIFIES ONCOLOGY
PORTFOLIO WITH ACQUISITION OF MIRATI THERAPEUTICS
    * TO ACQUIRE MIRATI FOR $58.00 PER SHARE, REPRESENTING $4.8
BILLION EQUITY VALUE AND UP TO $5.8 BILLION
    * ENTERED INTO A DEFINITIVE MERGER AGREEMENT UNDER WHICH CO
HAS
AGREED TO ACQUIRE MIRATI FOR $58.00 PER SHARE IN CASH
    * TRANSACTION IS EXPECTED BE DILUTIVE TO CO'S NON-GAAP EPS
BY
ABOUT $0.35 PER SHARE IN FIRST 12 MONTHS
    * EXPECTS TO FINANCE ACQUISITION WITH A COMBINATION OF CASH
AND
DEBT

Source text for Eikon:  ID:nBw5pNbhva 
Further company coverage:  BMY.N 

 ((Reuters.Briefs@thomsonreuters.com;))